View Filing Data

Print Document View Excel Document

Cover Page	6 Months Ended
Cover Page	Mar. 31, 2020 shares
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	001-4802
Entity Registrant Name	Becton, Dickinson and Company
Entity Central Index Key	0000010795
Current Fiscal Year End Date	--09-30
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-0760120
Entity Address, Address Line One	1 Becton Drive,
Entity Address, City or Town	Franklin Lakes,
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07417-1880
City Area Code	(201)
Local Phone Number	847-6800
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	271,776,378
Common Stock \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	Common stock, par value $1.00
Trading Symbol	BDX
Security Exchange Name	NYSE
Notes 1.000% due December 15, 2022 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.000% Notes due December 15, 2022
Trading Symbol	BDX22A
Security Exchange Name	NYSE
Notes 1.900% due December 15, 2026 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.900% Notes due December 15, 2026
Trading Symbol	BDX26
Security Exchange Name	NYSE
Notes 1.401% due May 24, 2023 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.401% Notes due May 24, 2023
Trading Symbol	BDX23A
Security Exchange Name	NYSE
Notes 3.020% due May 24, 2025 [Member] \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	3.020% Notes due May 24, 2025
Trading Symbol	BDX25
Security Exchange Name	NYSE
Notes 0.174% due June 4, 2021 [Member] \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	0.174% Notes due June 4, 2021
Trading Symbol	BDX/21
Security Exchange Name	NYSE
Notes 0.632% due June 4, 2023 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	0.632% Notes due June 4, 2023
Trading Symbol	BDX/23A
Security Exchange Name	NYSE
Notes 1.208% due June 4, 2026 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.208% Notes due June 4, 2026
Trading Symbol	BDX/26A
Security Exchange Name	NYSE

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2020	Sep. 30, 2019
Current Assets:
Cash and equivalents	$ 2,351	$ 536
Restricted cash	88	54
Short-term investments	6	30
Trade receivables, net	2,160	2,345
Inventories:
Materials	601	544
Work in process	357	318
Finished products	1,836	1,717
Inventories	2,793	2,579
Prepaid expenses and other	1,156	1,119
Total Current Assets	8,555	6,664
Property, Plant and Equipment	11,262	11,128
Less allowances for depreciation and amortization	5,598	5,469
Property, Plant and Equipment, Net	5,664	5,659
Goodwill	23,415	23,376
Developed Technology, Net	10,545	11,054
Customer Relationships, Net	3,261	3,424
Other Intangibles, Net	567	500
Other Assets	1,509	1,088
Total Assets	53,516	51,765
Current Liabilities:
Short-term debt	4,357	1,309
Payables, accrued expenses and other current liabilities	4,398	4,345
Total Current Liabilities	8,755	5,655
Long-Term Debt	16,809	18,081
Long-Term Employee Benefit Obligations	1,253	1,272
Deferred Income Taxes and Other Liabilities	5,747	5,676
Commitments and Contingencies
Shareholders’ Equity
Preferred stock	2	2
Common stock	347	347
Capital in excess of par value	16,288	16,270
Retained earnings	12,868	12,913
Deferred compensation	23	23
Common stock in treasury - at cost	(6,158)	(6,190)
Accumulated other comprehensive loss	(2,419)	(2,283)
Total Shareholders’ Equity	20,951	21,081
Total Liabilities and Shareholders’ Equity	$ 53,516	$ 51,765

Condensed Consolidated Statements of Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenues	$ 4,253	$ 4,195	$ 8,479	$ 8,355
Cost of products sold	2,520	2,221	4,766	4,408
Selling and administrative expense	1,025	1,089	2,146	2,161
Research and development expense	264	252	535	510
Acquisitions and other restructurings	75	101	161	191
Other operating expense, net	0	396	0	61
Total Operating Costs and Expenses	3,884	4,059	7,607	7,332
Operating Income	370	136	871	1,024
Interest expense	(134)	(171)	(270)	(342)
Interest income	2	18	3	6
Other (expense) income, net	(38)	20	(11)	30
Income Before Income Taxes	200	3	594	718
Income tax provision (benefit)	17	(17)	134	98
Net Income	183	20	461	619
Preferred stock dividends	(38)	(38)	(76)	(76)
Net income (loss) applicable to common shareholders	$ 145	$ (18)	$ 385	$ 544
Basic Earnings per Share (USD per share)	$ 0.53	$ (0.07)	$ 1.42	$ 2.02
Diluted Earnings per Share (USD per share)	0.53	(0.07)	1.40	1.98
Dividends per Common Share (USD per share)	$ 0.79	$ 0.77	$ 1.58	$ 1.54

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net Income	$ 183	$ 20	$ 461	$ 619
Other Comprehensive (Loss) Income, Net of Tax
Foreign currency translation adjustments	(125)	76	(99)	42
Defined benefit pension and postretirement plans	17	13	33	28
Cash flow hedges	(109)	(1)	(70)	0
Other Comprehensive (Loss) Income, Net of Tax	(218)	88	(136)	70
Comprehensive (Loss) Income	$ (35)	$ 108	$ 325	$ 689

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating Activities
Net income	$ 461	$ 619
Adjustments to net income to derive net cash provided by operating activities:
Depreciation and amortization	1,067	1,126
Share-based compensation	141	152
Deferred income taxes	136	109
Change in operating assets and liabilities	(258)	(531)
Pension obligation	49	(202)
Gain on sale of business	0	335
Product liability-related charge	0	331
Other, net	(128)	(25)
Net Cash Provided by Operating Activities	1,196	1,027
Investing Activities
Capital expenditures	(395)	(362)
Proceeds from divestitures, net	0	477
Other, net	(147)	(85)
Net Cash (Used for) Provided by Investing Activities	(542)	30
Financing Activities
Change in credit facility borrowings	210	0
Proceeds from long-term debt and term loans	1,900	0
Payments of debt and term loans	(305)	(905)
Dividends paid	(505)	(491)
Other, net	(90)	(135)
Net Cash Provided by (Used for) Financing Activities	1,210	(1,532)
Effect of exchange rate changes on cash and equivalents and restricted cash	(15)	5
Net increase (decrease) in cash and equivalents and restricted cash	1,849	(469)
Opening Cash and Equivalents and Restricted Cash	590	1,236
Closing Cash and Equivalents and Restricted Cash	$ 2,439	$ 767

Basis of Presentation	6 Months Ended
Basis of Presentation	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, in the opinion of the management of Becton, Dickinson and Company (the "Company" or "BD"), include all adjustments which are of a normal recurring nature, necessary for a fair presentation of the financial position and the results of operations and cash flows for the periods presented. However, the financial statements do not include all information and accompanying notes required for a presentation in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s 2019 Annual Report on Form 10-K. Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

Accounting Changes	6 Months Ended
Accounting Changes	Mar. 31, 2020
Accounting Changes and Error Corrections [Abstract]
Accounting Changes	Accounting Changes New Accounting Principle Adopted In February 2016, the Financial Accounting Standards Board ("FASB") issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet, as well as requires expanded disclosures regarding leasing arrangements. The Company adopted this standard on October 1, 2019 and elected certain practical expedients permitted under the transition guidance, including a transition method which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company also elected not to perform any reassessments relative to its expired and existing leases upon its adoption of the new requirements. The Company's adoption of this standard did not materially impact its condensed consolidated financial statements. Additional disclosures regarding the Company’s lease arrangements are provided in Note 15. New Accounting Principles Not Yet Adopted In June 2016, the FASB issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption on October 1, 2020. In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The standard is effective for the Company on October 1, 2020, but early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption.

Shareholders' Equity

6 Months Ended

Mar. 31, 2020

Stockholders' Equity Note [Abstract]

Shareholders' Equity

Changes in certain components of shareholders' equity for the first two quarters of fiscal years 2020 and 2019 were as follows:



	Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation			Treasury Stock
(Millions of dollars)	Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation			Shares (in thousands)		Amount
Balance at September 30, 2019	$	347	$	16,270		$	12,913		$	23		(76,260	)	$	(6,190	)
Net income	—		—			278			—			—		—
Common dividends ($0.79 per share)	—		—			(215		)	—			—		—
Preferred dividends	—		—			(38		)	—			—		—
Common stock issued for share-based compensation and other plans, net	—		(32		)	—			1			758		(38		)
Share-based compensation	—		82			—			—			—		—
Common stock held in trusts, net (a)	—		—			—			—			(12	)	—
Balance at December 31, 2019	$	347	$	16,320		$	12,938		$	24		(75,514	)	$	(6,228	)
Net income	—		—			183			—			—		—
Common dividends ($0.79 per share)	—		—			(215		)	—			—		—
Preferred dividends	—		—			(38		)	—			—		—
Common stock issued for share-based compensation and other plans, net	—		(91		)	—			(1		)	573		70
Share-based compensation	—		58			—			—			—		—
Common stock held in trusts, net (a)	—		—			—			—			30		—
Balance at March 31, 2020	$	347	$	16,288		$	12,868		$	23		(74,911	)	$	(6,158	)



	Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation			Treasury Stock
(Millions of dollars)	Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation			Shares (in thousands)		Amount
Balance at September 30, 2018	$	347	$	16,179		$	12,596		$	22		(78,463	)	$	(6,243	)
Net income	—		—			599			—			—		—
Common dividends ($0.77 per share)	—		—			(207		)	—			—		—
Preferred dividends	—		—			(38		)	—			—		—
Common stock issued for share-based compensation and other plans, net	—		(97		)	—			2			851		9
Share-based compensation	—		92			—			—			—		—
Common stock held in trusts, net (a)	—		—			—			—			(12	)	—
Effect of change in accounting principles	—		—			68			—			—		—
Balance at December 31, 2018	$	347	$	16,174		$	13,018		$	24		(77,624	)	$	(6,235	)
Net income	—		—			20			—			—		—
Common dividends ($0.77 per share)	—		—			(208		)	—			—		—
Preferred dividends	—		—			(38		)	—			—		—
Common stock issued for share-based compensation and other plans, net	—		(57		)	(1		)	(1		)	618		42
Share-based compensation	—		60			—			—			—		—
Common stock held in trusts, net (a)	—		—			—			—			50		—
Balance at March 31, 2019	$	347	$	16,177		$	12,792		$	23		(76,955	)	$	(6,192	)


(a)	Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.

The components and changes of Accumulated other comprehensive income (loss) for the first two quarters of fiscal years 2020 and 2019 were as follows:



(Millions of dollars)	Total			Foreign Currency Translation			Benefit Plans			Cash Flow Hedges
Balance at September 30, 2019	$	(2,283	)	$	(1,256	)	$	(1,005	)	$	(23	)
Other comprehensive income before reclassifications, net of taxes	63			26			—			37
Amounts reclassified into income, net of taxes	19			—			17			2
Balance at December 31, 2019	$	(2,202	)	$	(1,230	)	$	(988	)	$	16
Other comprehensive loss before reclassifications, net of taxes	(237		)	(125		)	—			(111		)
Amounts reclassified into income, net of taxes	19			—			17			2
Balance at March 31, 2020	$	(2,419	)	$	(1,355	)	$	(971	)	$	(93	)



(Millions of dollars)	Total			Foreign Currency Translation			Benefit Plans			Cash Flow Hedges
Balance at September 30, 2018	$	(1,909	)	$	(1,162	)	$	(729	)	$	(17	)
Other comprehensive (loss) income before reclassifications, net of taxes	(32		)	(35		)	3			(1		)
Amounts reclassified into income, net of taxes	14			—			13			1
Balance at December 31, 2018	$	(1,927	)	$	(1,197	)	$	(714	)	$	(16	)
Other comprehensive income (loss) before reclassifications, net of taxes	74			76			—			(2		)
Amounts reclassified into income, net of taxes	14			—			13			1
Balance at March 31, 2019	$	(1,839	)	$	(1,121	)	$	(701	)	$	(17	)

The amounts of foreign currency translation recognized in other comprehensive income during the three and six months ended March 31, 2020 and 2019 included net gains (losses) relating to net investment hedges. The amounts recognized in other comprehensive income relating to cash flow hedges during the three and six months ended March 31, 2020 related to forward starting interest rate swaps. Additional disclosures regarding the Company's derivatives are provided in Note 12.

Earnings Per Share

6 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Earnings per Share

The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:



	Three Months Ended March 31,		Six Months Ended March 31,
	2020	2019	2020	2019
Average common shares outstanding	272,014	269,882	271,555	269,454
Dilutive share equivalents from share-based plans	3,023	—	3,618	4,975
Average common and common equivalent shares outstanding – assuming dilution	275,037	269,882	275,173	274,429

Share equivalents excluded from the diluted shares outstanding calculation because the result would have been antidilutive:
Mandatory convertible preferred stock	11,685	11,685	11,685	11,685
Share-based plans	—	4,405	—	—

In accordance with the terms of the Company's mandatory convertible preferred stock, on the mandatory conversion date of May 1, 2020, the 2.475 million mandatory convertible preferred shares that were issued in May 2017 in connection with the Company's acquisition of C.R. Bard, Inc. ("Bard") were converted into 11.703 million shares of BD common stock.

Contingencies	6 Months Ended
Contingencies	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. GAAP, the Company establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the civil investigative demand served by the Department of Justice, as discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows. Product Liability Matters The Company believes that certain settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers, or, in some circumstances, indemnification obligations to the Company from other parties, which if disputed, the Company intends to vigorously contest. Amounts recovered under the Company’s product liability insurance policies or indemnification arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available. Hernia Product Claims As of March 31, 2020, the Company is defending approximately 16,815 product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The majority of those claims are currently pending in a coordinated proceeding in Rhode Island State Court, but claims are also pending in other state and/or federal court jurisdictions. In addition, those claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. From time to time, the Company engages in resolution discussions with plaintiffs’ law firms regarding certain of the Hernia Product Claims, but the Company also intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. Trials are scheduled throughout 2020 in various state and/or federal courts, with the first trial currently scheduled for June 2020 in Rhode Island. The Company expects additional trials of Hernia Product Claims to take place over the next 12 months. In August 2018, a new hernia multi-district litigation (“MDL”) was ordered to be established in the Southern District of Ohio. The Company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity. Women’s Health Product Claims As of March 31, 2020, the Company is defending approximately 580 product liability claims involving the Company’s line of pelvic mesh devices. The majority of those claims are currently pending in various federal court jurisdictions, and a coordinated proceeding in New Jersey State Court, but claims are also pending in other state court jurisdictions. In addition, those claims include putative class actions filed in the United States. Not included in the figures above are approximately 1,005 filed and unfiled claims that have been asserted or threatened against the Company but lack sufficient information to determine whether a pelvic mesh device of the Company is actually at issue. The claims identified above also include products manufactured by both the Company and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of the Company. Medtronic has an obligation to defend and indemnify the Company with respect to any product defect liability relating to products its subsidiaries had manufactured. In July 2015, the Company reached an agreement with Medtronic in which Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by the Company under supply agreements with Medtronic. In June 2017, the Company amended the agreement with Medtronic to transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on terms similar to the July 2015 agreement, including with respect to the obligation to make payments to Medtronic towards these potential settlements. As of March 31, 2020, the Company has paid Medtronic $141 million towards these potential settlements. The Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. The foregoing lawsuits, unfiled claims, putative class actions, and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims.” The Women’s Health Product Claims generally seek damages for personal injury allegedly resulting from use of the products. As of March 31, 2020, the Company has reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately 15,220 of the Women’s Health Product Claims. The Company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which are not included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. The Company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements. Starting in 2014 in the MDL, the court entered certain pre-trial orders requiring trial work up and remand of a significant number of Women’s Health Product Claims, including an order entered in the MDL on January 30, 2018, that requires the work up and remand of all remaining unsettled cases (the “WHP Pre-Trial Orders”). The WHP Pre-Trial Orders may result in material additional costs or trial verdicts in future periods in defending Women’s Health Product Claims. Trials are anticipated throughout 2020 in state and federal courts. A trial in the New Jersey coordinated proceeding began in March 2018, and in April 2018 a jury entered a verdict against the Company in the total amount of $68 million ($33 million compensatory; $35 million punitive). The Company is in the process of appealing that verdict. The Company expects additional trials of Women’s Health Product Claims to take place over the next 12 months, which may potentially include consolidated trials. During the course of engaging in settlement discussions with plaintiffs’ law firms, the Company has learned, and may in future periods learn, additional information regarding these and other unfiled claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. Filter Product Claims As of March 31, 2020, the Company is defending approximately 1,785 product liability claims involving the Company’s line of inferior vena cava filters (collectively, the “Filter Product Claims”). The majority of those claims were previously pending in an MDL in the United States District Court for the District of Arizona, but those MDL claims either have been, or are in the process of being, remanded to various federal jurisdictions. Filter Product Claims are also pending in various state court jurisdictions, including a coordinated proceeding in Arizona State Court. In addition, those claims include putative class actions filed in the United States and Canada. The Filter Product Claims generally seek damages for personal injury allegedly resulting from use of the products. The Company has limited information regarding the nature and quantity of certain of the Filter Product Claims. The Company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. On May 31, 2019, the MDL Court ceased accepting direct filings or transfers into the Filter Product Claims MDL and, as noted above, remands for non-settled cases have begun and are expected to continue over the next three months. Federal and state court trials are scheduled throughout 2020. As of March 31, 2020, the Company entered into settlement agreements and/or settlement agreements in principle for approximately 7,300 cases. On March 30, 2018, a jury in the first MDL trial found the Company liable for negligent failure to warn and entered a verdict in favor of plaintiffs. The jury found the Company was not liable for (a) strict liability design defect; (b) strict liability failure to warn; and (c) negligent design. The Company has appealed that verdict. On June 1, 2018, a jury in the second MDL trial unanimously found in favor of the Company on all claims. On August 17, 2018, the Court entered summary judgment in favor of the Company on all claims in the third MDL trial. On October 5, 2018, a jury in the fourth MDL trial unanimously found in favor of the Company on all claims. The Company expects additional trials of Filter Product Claims may take place over the next 12 months. In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters. In connection with the settlement of a prior litigation with certain of the Company's insurance carriers, an agreement with the Company's insurance carriers was reached to reimburse the Company for certain future costs incurred in connection with Filter Product Claims up to an agreed amount. For certain product liability claims or lawsuits, the Company does not maintain or has limited remaining insurance coverage. Other Legal Matters Since early 2013, the Company has received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the Company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The Company is cooperating with these requests. Although the Company has had, and continues to have, discussions with the State Attorneys General with respect to overall potential resolution of this matter, there can be no assurance that a resolution will be reached or what the terms of any such resolution may be. In July 2017, a civil investigative demand was served by the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec^® and QuantaFlo^TM devices. The Company is cooperating with these requests. Since it is not feasible to predict the outcome of these matters, the Company cannot give any assurances that the resolution of these matters will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity. The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the Company’s business and/or results of operations. On February 27, 2020, a putative class action captioned Kabak v. Becton, Dickinson and Company, et al., Civ. No. 2:20-cv-02155 (SRC) (CLW), was filed in the U.S. District Court for the District of New Jersey against the Company and certain of its officers. The complaint, which purports to be brought on behalf of all persons (other than defendants) who purchased or otherwise acquired the Company's common stock from November 5, 2019 through February 5, 2020, asserts claims for purported violations of Sections 10 and 20 of the Securities Exchange Act of 1934 and SEC Rule 10b-5 promulgated thereunder, and seeks, among other things, damages and costs. The complaint alleges that defendants concealed material information regarding Alaris^TM infusion pumps, including that (1) certain pumps exhibited software errors, (2) the Company was investing in remediation efforts as opposed to other enhancements and (3) the Company was thus reasonably likely to recall certain pumps and/or experience regulatory delays. These alleged omissions, the complaint asserts, rendered certain public statements about the Company’s business, operations and prospects false or misleading, causing investors to purchase stock at an inflated price. The Company believes these claims are without merit and intends to vigorously defend this action. On April 27, 2020, three putative stockholders, including the named plaintiff in the Kabak complaint, filed motions to be appointed lead plaintiff and for their counsel to be appointed lead counsel pursuant to the Private Securities Litigation Reform Act of 1995. Those motions remain pending. The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses to these suits pending against the Company and is engaged in a vigorous defense of each of these matters. Litigation Reserves The Company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time. In the second and fourth quarters of fiscal year 2019, the Company recorded pre-tax charges to Other operating expense, net, of approximately $331 million and $582 million, respectively, related to certain of the product liability matters discussed above under the heading “Product Liability Matters,” including the related legal defense costs. The Company recorded these charges based on additional information obtained during the second and fourth quarters of fiscal year 2019. Accruals for the Company's product liability claims which are discussed above, as well as the related legal defense costs, amounted to approximately $2.3 billion at March 31, 2020 and $2.5 billion at September 30, 2019. These accruals, which are generally long-term in nature, are largely recorded within Deferred Income Taxes and Other Liabilities on the Company's condensed consolidated balance sheets. As of March 31, 2020 and September 30, 2019, the Company had $87 million and $53 million, respectively, in qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters. Payments to QSFs are recorded as a component of Restricted cash. The Company's expected recoveries related to product liability claims and related legal defense costs were approximately $117 million and $150 million at March 31, 2020 and September 30, 2019, respectively. A substantial amount of these expected recoveries at March 31, 2020 and September 30, 2019 related to the Company’s agreements with Medtronic related to certain Women’s Health Product Claims. The expected recoveries at March 31, 2020 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreements.

Revenues	6 Months Ended
Revenues	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue	Revenues The Company’s policies for recognizing sales have not changed from those described in the Company’s 2019 Annual Report on Form 10-K. The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through independent distribution channels and directly by BD through sales representatives. End-users of the Company's products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Measurement of Revenues The Company’s estimate of probable credit losses relating to trade receivables is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectable. Such amounts are not material to the Company's consolidated financial results. The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. The impact of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues. Effects of Revenue Arrangements on Consolidated Balance Sheets Capitalized contract costs associated with the costs to fulfill contracts for certain products in the Medication Management Solutions organizational unit are immaterial to the Company's condensed consolidated balance sheets. Commissions relating to revenues recognized over a period longer than one year are recorded as assets which are amortized over the period over which the revenues underlying the commissions are recognized. Capitalized contract costs related to such commissions are immaterial to the Company's condensed consolidated balance sheets. Contract liabilities for unearned revenue that is allocable to performance obligations, such as extended warranty and software maintenance contracts, which are performed over time are immaterial to the Company's consolidated financial results. The Company's liability for product warranties provided under its agreements with customers is not material to its condensed consolidated balance sheets. Remaining Performance Obligations The Company's obligations relative to service contracts and pending installations of equipment, primarily in the Company's Medication Management Solutions unit, represent unsatisfied performance obligations of the Company. The revenues under existing contracts with original expected durations of more than one year, which are attributable to products and/or services that have not yet been installed or provided are estimated to be approximately $1.7 billion at March 31, 2020. The Company expects to recognize the majority of this revenue over the next three years. Within the Company's Medication Management Solutions, Medication Delivery Solutions, Integrated Diagnostic Solutions, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related performance obligations, for contracts with original expected durations of more than one year, is estimated to be approximately $2.7 billion at March 31, 2020. This revenue will be recognized over the customer relationship period. Disaggregation of Revenues A disaggregation of the Company's revenues by segment, organizational unit and geographic region is provided in Note 7.

Segment Data

6 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Segment Data

The Company's organizational structure is based upon three principal business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.

Effective October 1, 2019, Life Sciences joined its former Preanalytical Systems and Diagnostic Systems organizational units to create a new Integrated Diagnostic Solutions organizational unit which focuses on driving growth and innovation around integrated specimen management to diagnostic solutions. The Integrated Diagnostic Solutions organizational unit consists of the following principal product lines:



Organizational Unit		Principal Product Lines
Integrated Diagnostic Solutions		Integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women’s health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays for testing of respiratory infections; microbiology laboratory automation and plated media for clinical and industrial applications.

Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues.



	Three Months Ended March 31,
(Millions of dollars)	2020						2019
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions (a)	$	518	$	386	$	904	$	482	$	446	$	928
Medication Management Solutions (a)	449		119		568		499		118		617
Diabetes Care	142		137		278		137		133		270
Pharmaceutical Systems	91		309		400		93		273		366
Total segment revenues	$	1,200	$	951	$	2,151	$	1,211	$	969	$	2,180

Life Sciences
Integrated Diagnostic Solutions
Preanalytical Systems	$	208	$	192	$	400	$	171	$	195	$	366
Diagnostic Systems	206		228		434		180		209		389
Total Integrated Diagnostic Solutions	413		420		833		350		404		755
Biosciences	108		172		280		120		177		297
Total segment revenues	$	522	$	591	$	1,113	$	470	$	582	$	1,052

Interventional
Surgery (b)	$	249	$	63	$	312	$	242	$	66	$	308
Peripheral Intervention (b)	242		157		399		225		162		387
Urology and Critical Care (b)	202		76		279		193		75		268
Total segment revenues	$	693	$	297	$	990	$	659	$	303	$	963

Total Company revenues	$	2,415	$	1,839	$	4,253	$	2,341	$	1,854	$	4,195


(a)	Prior-period amounts reflect the reclassification of U.S. revenues of $2 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.


(b)	Prior-period amounts reflect the total reclassifications of $31 million of U.S. revenues and $13 million of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.



	Six Months Ended March 31,
(Millions of dollars)	2020						2019
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions (a)	$	1,038	$	814	$	1,852	$	1,000	$	883	$	1,884
Medication Management Solutions (a)	912		231		1,143		1,007		236		1,242
Diabetes Care	281		266		547		282		261		544
Pharmaceutical Systems	174		525		699		161		485		646
Total segment revenues	$	2,404	$	1,836	$	4,241	$	2,450	$	1,865	$	4,316

Life Sciences
Integrated Diagnostic Solutions
Preanalytical Systems	$	410	$	388	$	798	$	371	$	387	$	758
Diagnostic Systems	390		446		835		355		416		771
Total Integrated Diagnostic Solutions	799		834		1,633		726		803		1,529
Biosciences	260		342		603		228		350		579
Total segment revenues	$	1,060	$	1,176	$	2,236	$	954	$	1,153	$	2,108

Interventional
Surgery (b)	$	505	$	133	$	638	$	488	$	130	$	618
Peripheral Intervention (b)	467		327		794		448		321		769
Urology and Critical Care (b)	409		161		570		388		158		545
Total segment revenues	$	1,381	$	621	$	2,002	$	1,323	$	609	$	1,932

Total Company revenues	$	4,845	$	3,634	$	8,479	$	4,728	$	3,628	$	8,355


(a)	Prior-period amounts reflect the reclassification of U.S. revenues of $3 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.


(b)	Prior-period amounts reflect the total reclassifications of $63 million of U.S. revenues and $28 million of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.

Segment income for the three and six-month periods was as follows:



	Three Months Ended March 31,						Six Months Ended March 31,
(Millions of dollars)	2020			2019			2020			2019
Income Before Income Taxes
Medical (a) (b)	$	443		$	599		$	1,007		$	1,265
Life Sciences (c)	285			293			646			598
Interventional	213			231			455			441
Total Segment Operating Income	941			1,123			2,109			2,303
Acquisitions and other restructurings	(75		)	(101		)	(161		)	(191		)
Net interest expense	(132		)	(153		)	(266		)	(336		)
Other unallocated items (d)	(534		)	(866		)	(1,087		)	(1,058		)
Total Income Before Income Taxes	$	200		$	3		$	594		$	718

(a)

The amounts for the three and six months ended March 31, 2020 include a probable estimate of future costs within the Medication Management Solutions unit associated with remediation efforts related to Alaris^TM infusion pumps of $199 million and $258 million, respectively, which were recorded to Cost of products sold. Based on the course of remediation efforts, it is possible that the estimate of future costs could increase over time.


(b)	The amounts for the three and six-month periods in 2019 included $65 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform.


(c)	The amounts for the three and six-month periods in 2020 include a charge of $39 million recorded to Cost of products sold to write down the carrying value of certain intangible assets in the Biosciences unit.

(d)

Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amounts for the three and six-month periods in 2019 include a pre-tax charge of $331 million related to certain product liability matters, which is further discussed in Note 5. In addition, the amount for the six months ended March 31, 2019 included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $335 million, which is further discussed in Note 9.

Benefit Plans

6 Months Ended

Mar. 31, 2020

Retirement Benefits [Abstract]

Benefit Plans

The Company has defined benefit pension plans covering certain employees in the United States and certain international locations. The measurement date used for these plans is September 30.

Net pension cost included the following components for the three and six months ended March 31:



	Three Months Ended March 31,						Six Months Ended March 31,
(Millions of dollars)	2020			2019			2020			2019
Service cost	$	39		$	33		$	79		$	68
Interest cost	21			26			43			54
Expected return on plan assets	(48		)	(45		)	(97		)	(91		)
Amortization of prior service credit	(3		)	(3		)	(7		)	(7		)
Amortization of loss	25			19			50			39
Net pension cost	$	34		$	31		$	68		$	63

The amounts provided above for amortization of prior service credit and amortization of loss represent the reclassifications of prior service credits and net actuarial losses that were recognized in Accumulated other comprehensive income (loss) in prior periods. All components of the Company’s net periodic pension cost, aside from service cost, are recorded to Other income (expense), net on its condensed consolidated statements of income.

Divestiture	6 Months Ended
Divestiture	Mar. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Divestiture	DivestitureIn October 2018, the Company completed the sale of its Life Sciences segment's Advanced Bioprocessing business. The Company recognized a pre-tax gain on the sale of approximately $335 million which was recorded as a component of Other operating expense, net in the first quarter of fiscal year 2019.

Business Restructuring Charges

6 Months Ended

Mar. 31, 2020

Restructuring and Related Activities [Abstract]

Business Restructuring Charges

The Company incurred restructuring costs during the six months ended March 31, 2020, in connection with the Company's acquisition of Bard and portfolio rationalization initiatives, which were largely recorded within Acquisitions and other restructurings. Restructuring liability activity for the six months ended March 31, 2020 was as follows:



(Millions of dollars)	Employee Termination						Other						Total
	Bard			Other Initiatives			Bard (a)			Other Initiatives			Bard			Other Initiatives
Balance at September 30, 2019	$	22		$	31		$	1		$	3		$	23		$	34
Charged to expense	6			(2		)	23			14			29			12
Cash payments	(12		)	(23		)	(5		)	(12		)	(17		)	(35		)
Non-cash settlements	—			—			(16		)	(2		)	(16		)	(2		)
Balance at March 31, 2020	$	16		$	6		3			$	3		$	19		$	9

(a)

Largely represents the cost associated with certain pre-acquisition equity awards of Bard which, to encourage post-acquisition employee retention, were converted to BD equity awards with substantially the same terms and conditions as were applicable under such Bard awards immediately prior to the acquisition date.

Intangible Assets

6 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangible assets consisted of:



	March 31, 2020				September 30, 2019
(Millions of dollars)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Amortized intangible assets
Developed technology	$	13,985	$	3,440	$	13,960	$	2,906
Customer relationships	4,606		1,345		4,608		1,183
Product rights	106		61		110		60
Trademarks	407		110		407		102
Patents and other	493		315		445		305
Amortized intangible assets	$	19,597	$	5,271	$	19,530	$	4,555
Unamortized intangible assets
Acquired in-process research and development (a)	$	46			$	1
Trademarks	2				2
Unamortized intangible assets	$	48			$	3


(a)	The increase in the carrying value of assets in 2020 was attributable to an immaterial acquisition which occurred during the second quarter of fiscal year 2020.

Intangible amortization expense for the three months ended March 31, 2020 and 2019 was $347 million and $376 million, respectively. Intangible amortization expense for the six months ended March 31, 2020 and 2019 was $693 million and $754 million, respectively.

The following is a reconciliation of goodwill by business segment:



(Millions of dollars)	Medical			Life Sciences			Interventional			Total
Goodwill as of September 30, 2019	$	9,989		$	772		$	12,615		$	23,376
Acquisitions (a)	10			58			—			68
Currency translation	(2		)	(1		)	(26		)	(29		)
Goodwill as of March 31, 2020	$	9,997		$	828		$	12,589		$	23,415

(a)

Represents goodwill recognized relative to certain acquisitions which were not material individually or in the aggregate.

Derivative Instruments and Hedging Activities

6 Months Ended

Mar. 31, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities

The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items have on financial position, financial performance, and cash flows are provided below.

Foreign Currency Risks and Related Strategies

The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts. In order to mitigate foreign currency exposure relating to its investments in certain foreign subsidiaries, the Company has hedged the currency risk associated with those investments with instruments, such as foreign currency-denominated debt, cross-currency swaps and currency exchange contracts, which are designated as net investment hedges.

Hedges of the transactional foreign exchange exposures resulting primarily from intercompany payables and receivables are undesignated hedges. As such, the gains or losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. The net amounts recognized in Other (expense) income, net, during the three and six months ended March 31, 2020 and 2019 were immaterial to the Company's consolidated financial results. The total notional amounts of the Company’s outstanding foreign exchange contracts as of March 31, 2020 and September 30, 2019 were $1.2 billion and $2.3 billion, respectively.

Certain of the Company's foreign currency-denominated long-term notes outstanding, which had a total carrying value of $1.4 billion as of March 31, 2020 and September 30, 2019, were designated as, and were effective as, economic hedges of net investments in certain of the Company's foreign subsidiaries. The Company has entered into cross-currency swaps, all of which are designated and effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. The notional amounts of the cross-currency swaps were $3.0 billion and $2.3 billion as of March 31, 2020 and September 30, 2019, respectively.

Net gains or losses relating to the net investment hedges, which are attributable to changes in the foreign currencies to U.S. dollar spot exchange rates, are recorded as accumulated foreign currency translation in Other comprehensive income (loss). Upon the termination of a net investment hedge, any net gain or loss included in Accumulated other comprehensive income (loss) relative to the investment hedge remains until the foreign subsidiary investment is disposed of or is substantially liquidated.

Net gains (losses) recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges for the three and six-month periods were as follows:



	Three Months Ended March 31,					Six Months Ended March 31,
(Millions of dollars)	2020		2019			2020		2019
Foreign currency-denominated debt	$	44	$	(18	)	$	10	$	41
Cross-currency swaps	$	193	$	—		$	141	$	—

Interest Rate Risks and Related Strategies

The Company’s policy is to manage interest rate exposure using a mix of fixed and variable rate debt. The Company periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either fair value or cash flow hedges.

For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates.

The total notional amount of the Company’s outstanding interest rate swaps designated as fair value hedges was $375 million at March 31, 2020 and September 30, 2019. The outstanding swaps represent fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR. Changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt. The amounts recorded during the three and six months ended March 31, 2020 and 2019 for changes in the fair value of these hedges were immaterial to the Company's consolidated financial results.

Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in Other comprehensive income (loss). If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings over the remaining life of the hedged debt. The net realized loss related to terminated interest rate swaps expected to be reclassified and recorded in Interest expense within the next 12 months is $6 million, net of tax.

The total notional amount of the Company's outstanding forward starting interest rate swaps was $1.5 billion at March 31, 2020 and September 30, 2019. The Company entered into these contracts in the fourth quarter of fiscal year 2019 to mitigate its exposure to interest rate risk. The Company recorded after-tax losses of $111 million and $74 million in Other comprehensive income (loss) relating to these interest rate hedges during the three and six months ended March 31, 2020, respectively.

Other Risk Exposures

The Company purchases resins, which are oil-based components used in the manufacture of certain products. Significant increases in world oil prices that lead to increases in resin purchase costs could impact future operating results. From time to time, the Company has managed price risks associated with these commodity purchases through commodity derivative forward contracts. The Company had no outstanding commodity derivative forward contracts at March 31, 2020 and the amount outstanding as of September 30, 2019 was immaterial to the Company's consolidated financial results.

Financial Statement Effects

The fair values of derivative instruments outstanding at March 31, 2020 and September 30, 2019 were not material to the Company's consolidated balance sheets.

The amounts reclassified from accumulated other comprehensive income relating to cash flow hedges during the three and six months ended March 31, 2020 and 2019 were not material to the Company's consolidated financial results.

Financial Instruments and Fair Value Measurements

6 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Financial Instruments and Fair Value Measurements

The following reconciles cash and equivalents and restricted cash reported within the Company's consolidated balance sheets at March 31, 2020 and September 30, 2019 to the total of these amounts shown on the Company's consolidated statements of cash flows:



(Millions of dollars)	March 31, 2020		September 30, 2019
Cash and equivalents	$	2,351	$	536
Restricted cash	88		54
Cash and equivalents and restricted cash	$	2,439	$	590

Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted cash consists of cash restricted from withdrawal and usage except for certain product liability matters.

The Company’s cash and equivalents include institutional money market accounts which permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions, which are considered Level 1 inputs in the fair value hierarchy. The fair values of these accounts were $1.8 billion and $39 million at March 31, 2020 and September 30, 2019, respectively. The Company’s remaining cash and equivalents, excluding restricted cash, were $516 million and $497 million at March 31, 2020 and September 30, 2019, respectively.

Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments consist of instruments with maturities greater than three months and less than one year.

Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments, which are considered Level 2 inputs in the fair value hierarchy. The fair value of long-term debt was $17.2 billion and $19.2 billion at March 31, 2020 and September 30, 2019, respectively. The fair value of the current portion of long-term debt was $2.4 billion and $1.3 billion at March 31, 2020 and September 30, 2019, respectively.

All other instruments measured by the Company at fair value, including derivatives and contingent consideration liabilities, are immaterial to the Company's consolidated balance sheets.

Nonrecurring Fair Value Measurements

In the second quarter of fiscal year 2020, the Company recorded a charge to Cost of products sold of $39 million to write down the carrying value of certain intangible assets in the Biosciences unit. The amount recognized in the second quarter of 2020 was recorded to adjust the carrying amount of assets to the assets' fair values, which were estimated, based upon a market participant's perspective, using Level 3 inputs, as values were estimated using the income approach.

Transfers of trade receivables

Over the normal course of its business activities, the Company transfers certain trade receivable assets to third parties under factoring agreements. Per the terms of these agreements, the Company surrenders control over its trade receivables upon transfer. Accordingly, the Company accounts for the transfers as sales of trade receivables by recognizing an increase to Cash and equivalents and a decrease to Trade receivables, net when proceeds from the transactions are received. The Company’s balance of Trade receivables, net at March 31, 2020 excludes trade receivables of $246 million that have been transferred to third parties under factoring arrangements. The costs incurred by the Company in connection with factoring activities were not material to its consolidated financial results. The Company’s transfers of trade receivables during the six months ended March 31, 2019 were not material to its consolidated financial results.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Debt	6 Months Ended
Debt	Mar. 31, 2020
Debt Disclosure [Abstract]
Debt	Debt While the Company deemed its liquidity sufficient to fund its operations and meet its obligations, the Company has taken steps, as a precautionary measure, to preserve its financial flexibility in light of the uncertainty in the global markets resulting from the COVID-19 pandemic. In March 2020, the Company entered into a 364-day $1.4 billion senior unsecured term loan facility and later in March 2020, this agreement was amended to increase the borrowing capacity available under the facility to $2.0 billion. Borrowings outstanding under the term loan facility were $1.9 billion at March 31, 2020 and these proceeds are included in the Company's balance of Cash and equivalents at March 31, 2020. In April 2020, the Company entered into a supplement to its existing $2.25 billion senior unsecured revolving credit facility which increased the revolving commitments available to the Company under revolving credit facility by $381 million. As such, the Company's senior unsecured revolving credit facility currently provides borrowings of up to $2.63 billion. Proceeds from this facility are used to fund general corporate needs and borrowings outstanding under the revolving credit facility at March 31, 2020 were $695 million.

Leases

6 Months Ended

Mar. 31, 2020

Leases [Abstract]

Leases of Lessee Disclosure [Text Block]

Leases

The Company leases real estate, vehicles and other equipment which are used in the Company’s manufacturing, administrative and research and development activities. The Company identifies a contract that contains a lease as one which conveys a right, either explicitly or implicitly, to control the use of an identified asset in exchange for consideration. The Company’s lease arrangements are generally classified as operating leases. These arrangements have remaining terms ranging from less than one year to approximately 25 years and the weighted-average remaining lease term of the Company’s leases is approximately 7.5 years. An option to renew or terminate the current term of a lease arrangement is included in the lease term if the Company is reasonably certain to exercise that option.

The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet. For the longer-term lease arrangements that are recognized on the Company’s consolidated balance sheet, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. The costs associated with the Company’s short-term leases, as well as variable costs relating to the Company’s lease arrangements, are not material to its consolidated financial results.

The implicit interest rates of the Company’s lease arrangements are generally not readily determinable and as such, the Company applies an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. The weighted-average incremental borrowing rate that has been applied to measure the Company’s lease liabilities is 2.3%.

The Company’s lease costs recorded in its consolidated statements of income for the three and six months ended March 31, 2020 were $32 million and $65 million, respectively. Cash payments arising from the Company’s lease arrangements are reflected on its condensed consolidated statement of cash flows as outflows used for operating activities. The right-of-use assets and lease liabilities recognized on the Company’s condensed consolidated balance sheet as of March 31, 2020 were as follows:



(Millions of dollars)	March 31, 2020
Right-of-use assets recorded in Other Assets	$	427
Current lease liabilities recorded in Payables, accrued expenses and other current liabilities	$	103
Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities	$	345

The Company’s payments due under its operating leases are as follows:



(Millions of dollars)
Remaining for 2020	$	58
2021	102
2022	83
2023	55
2024	36
Thereafter	164
Total payments due	499
Less: imputed interest	50
Total	$	448

The Company’s future minimum rental commitments on non-cancelable leases at September 30, 2019, as disclosed in the Company’s 2019 Annual Report on Form 10-K, were as follows:



(Millions of dollars)
2020	$	122
2021	103
2022	83
2023	57
2024	56
Thereafter	123
Total	$	546

Accounting Changes (Policies)	6 Months Ended
Accounting Changes (Policies)	Mar. 31, 2020
Accounting Changes and Error Corrections [Abstract]
New Accounting Principles Adopted	New Accounting Principle Adopted In February 2016, the Financial Accounting Standards Board ("FASB") issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet, as well as requires expanded disclosures regarding leasing arrangements. The Company adopted this standard on October 1, 2019 and elected certain practical expedients permitted under the transition guidance, including a transition method which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company also elected not to perform any reassessments relative to its expired and existing leases upon its adoption of the new requirements. The Company's adoption of this standard did not materially impact its condensed consolidated financial statements. Additional disclosures regarding the Company’s lease arrangements are provided in Note 15. New Accounting Principles Not Yet Adopted In June 2016, the FASB issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption on October 1, 2020. In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The standard is effective for the Company on October 1, 2020, but early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption.
Commitments and Contingencies	Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. GAAP, the Company establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the civil investigative demand served by the Department of Justice, as discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows.
Revenue	Measurement of Revenues The Company’s estimate of probable credit losses relating to trade receivables is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectable. Such amounts are not material to the Company's consolidated financial results. The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. The impact of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues.
Derivatives	Hedges of the transactional foreign exchange exposures resulting primarily from intercompany payables and receivables are undesignated hedges. The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items have on financial position, financial performance, and cash flows are provided below. The Company’s policy is to manage interest rate exposure using a mix of fixed and variable rate debt. The Company periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either fair value or cash flow hedges. For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates. The total notional amount of the Company’s outstanding interest rate swaps designated as fair value hedges was $375 million at March 31, 2020 and September 30, 2019. The outstanding swaps represent fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR. Changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt. The amounts recorded during the three and six months ended March 31, 2020 and 2019 for changes in the fair value of these hedges were immaterial to the Company's consolidated financial results. Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in Other comprehensive income (loss). If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings over the remaining life of the hedged debt.
Fair Value of Financial Instruments	The Company’s cash and equivalents include institutional money market accounts which permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions, which are considered Level 1 inputs in the fair value hierarchy. The fair values of these accounts were $1.8 billion and $39 million at March 31, 2020 and September 30, 2019, respectively. The Company’s remaining cash and equivalents, excluding restricted cash, were $516 million and $497 million at March 31, 2020 and September 30, 2019, respectively. Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments consist of instruments with maturities greater than three months and less than one year. Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments, which are considered Level 2 inputs in the fair value hierarchy. The fair value of long-term debt was $17.2 billion and $19.2 billion at March 31, 2020 and September 30, 2019, respectively. The fair value of the current portion of long-term debt was $2.4 billion and $1.3 billion at March 31, 2020 and September 30, 2019, respectively. All other instruments measured by the Company at fair value, including derivatives and contingent consideration liabilities, are immaterial to the Company's consolidated balance sheets.
Lessee, Leases	The Company identifies a contract that contains a lease as one which conveys a right, either explicitly or implicitly, to control the use of an identified asset in exchange for consideration. The Company’s lease arrangements are generally classified as operating leases. These arrangements have remaining terms ranging from less than one year to approximately 25 years and the weighted-average remaining lease term of the Company’s leases is approximately 7.5 years. An option to renew or terminate the current term of a lease arrangement is included in the lease term if the Company is reasonably certain to exercise that option.The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet. For the longer-term lease arrangements that are recognized on the Company’s consolidated balance sheet, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement.
Short-term Leases	The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet.

Shareholders' Equity (Tables)

6 Months Ended

Mar. 31, 2020

Stockholders' Equity Note [Abstract]

Schedule of Shareholders Equity

Changes in certain components of shareholders' equity for the first two quarters of fiscal years 2020 and 2019 were as follows:



	Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation			Treasury Stock
(Millions of dollars)	Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation			Shares (in thousands)		Amount
Balance at September 30, 2019	$	347	$	16,270		$	12,913		$	23		(76,260	)	$	(6,190	)
Net income	—		—			278			—			—		—
Common dividends ($0.79 per share)	—		—			(215		)	—			—		—
Preferred dividends	—		—			(38		)	—			—		—
Common stock issued for share-based compensation and other plans, net	—		(32		)	—			1			758		(38		)
Share-based compensation	—		82			—			—			—		—
Common stock held in trusts, net (a)	—		—			—			—			(12	)	—
Balance at December 31, 2019	$	347	$	16,320		$	12,938		$	24		(75,514	)	$	(6,228	)
Net income	—		—			183			—			—		—
Common dividends ($0.79 per share)	—		—			(215		)	—			—		—
Preferred dividends	—		—			(38		)	—			—		—
Common stock issued for share-based compensation and other plans, net	—		(91		)	—			(1		)	573		70
Share-based compensation	—		58			—			—			—		—
Common stock held in trusts, net (a)	—		—			—			—			30		—
Balance at March 31, 2020	$	347	$	16,288		$	12,868		$	23		(74,911	)	$	(6,158	)



	Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation			Treasury Stock
(Millions of dollars)	Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation			Shares (in thousands)		Amount
Balance at September 30, 2018	$	347	$	16,179		$	12,596		$	22		(78,463	)	$	(6,243	)
Net income	—		—			599			—			—		—
Common dividends ($0.77 per share)	—		—			(207		)	—			—		—
Preferred dividends	—		—			(38		)	—			—		—
Common stock issued for share-based compensation and other plans, net	—		(97		)	—			2			851		9
Share-based compensation	—		92			—			—			—		—
Common stock held in trusts, net (a)	—		—			—			—			(12	)	—
Effect of change in accounting principles	—		—			68			—			—		—
Balance at December 31, 2018	$	347	$	16,174		$	13,018		$	24		(77,624	)	$	(6,235	)
Net income	—		—			20			—			—		—
Common dividends ($0.77 per share)	—		—			(208		)	—			—		—
Preferred dividends	—		—			(38		)	—			—		—
Common stock issued for share-based compensation and other plans, net	—		(57		)	(1		)	(1		)	618		42
Share-based compensation	—		60			—			—			—		—
Common stock held in trusts, net (a)	—		—			—			—			50		—
Balance at March 31, 2019	$	347	$	16,177		$	12,792		$	23		(76,955	)	$	(6,192	)

(a)

Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.

Schedule of Accumulated Other Comprehensive Income (Loss)

The components and changes of Accumulated other comprehensive income (loss) for the first two quarters of fiscal years 2020 and 2019 were as follows:



(Millions of dollars)	Total			Foreign Currency Translation			Benefit Plans			Cash Flow Hedges
Balance at September 30, 2019	$	(2,283	)	$	(1,256	)	$	(1,005	)	$	(23	)
Other comprehensive income before reclassifications, net of taxes	63			26			—			37
Amounts reclassified into income, net of taxes	19			—			17			2
Balance at December 31, 2019	$	(2,202	)	$	(1,230	)	$	(988	)	$	16
Other comprehensive loss before reclassifications, net of taxes	(237		)	(125		)	—			(111		)
Amounts reclassified into income, net of taxes	19			—			17			2
Balance at March 31, 2020	$	(2,419	)	$	(1,355	)	$	(971	)	$	(93	)



(Millions of dollars)	Total			Foreign Currency Translation			Benefit Plans			Cash Flow Hedges
Balance at September 30, 2018	$	(1,909	)	$	(1,162	)	$	(729	)	$	(17	)
Other comprehensive (loss) income before reclassifications, net of taxes	(32		)	(35		)	3			(1		)
Amounts reclassified into income, net of taxes	14			—			13			1
Balance at December 31, 2018	$	(1,927	)	$	(1,197	)	$	(714	)	$	(16	)
Other comprehensive income (loss) before reclassifications, net of taxes	74			76			—			(2		)
Amounts reclassified into income, net of taxes	14			—			13			1
Balance at March 31, 2019	$	(1,839	)	$	(1,121	)	$	(701	)	$	(17	)

Earnings Per Share (Tables)

6 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share

The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:



	Three Months Ended March 31,		Six Months Ended March 31,
	2020	2019	2020	2019
Average common shares outstanding	272,014	269,882	271,555	269,454
Dilutive share equivalents from share-based plans	3,023	—	3,618	4,975
Average common and common equivalent shares outstanding – assuming dilution	275,037	269,882	275,173	274,429

Share equivalents excluded from the diluted shares outstanding calculation because the result would have been antidilutive:
Mandatory convertible preferred stock	11,685	11,685	11,685	11,685
Share-based plans	—	4,405	—	—

Segment Data (Tables)

6 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Revenue from External Customers by Geographic Area

Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues.



	Three Months Ended March 31,
(Millions of dollars)	2020						2019
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions (a)	$	518	$	386	$	904	$	482	$	446	$	928
Medication Management Solutions (a)	449		119		568		499		118		617
Diabetes Care	142		137		278		137		133		270
Pharmaceutical Systems	91		309		400		93		273		366
Total segment revenues	$	1,200	$	951	$	2,151	$	1,211	$	969	$	2,180

Life Sciences
Integrated Diagnostic Solutions
Preanalytical Systems	$	208	$	192	$	400	$	171	$	195	$	366
Diagnostic Systems	206		228		434		180		209		389
Total Integrated Diagnostic Solutions	413		420		833		350		404		755
Biosciences	108		172		280		120		177		297
Total segment revenues	$	522	$	591	$	1,113	$	470	$	582	$	1,052

Interventional
Surgery (b)	$	249	$	63	$	312	$	242	$	66	$	308
Peripheral Intervention (b)	242		157		399		225		162		387
Urology and Critical Care (b)	202		76		279		193		75		268
Total segment revenues	$	693	$	297	$	990	$	659	$	303	$	963

Total Company revenues	$	2,415	$	1,839	$	4,253	$	2,341	$	1,854	$	4,195


(a)	Prior-period amounts reflect the reclassification of U.S. revenues of $2 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.


(b)	Prior-period amounts reflect the total reclassifications of $31 million of U.S. revenues and $13 million of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.



	Six Months Ended March 31,
(Millions of dollars)	2020						2019
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions (a)	$	1,038	$	814	$	1,852	$	1,000	$	883	$	1,884
Medication Management Solutions (a)	912		231		1,143		1,007		236		1,242
Diabetes Care	281		266		547		282		261		544
Pharmaceutical Systems	174		525		699		161		485		646
Total segment revenues	$	2,404	$	1,836	$	4,241	$	2,450	$	1,865	$	4,316

Life Sciences
Integrated Diagnostic Solutions
Preanalytical Systems	$	410	$	388	$	798	$	371	$	387	$	758
Diagnostic Systems	390		446		835		355		416		771
Total Integrated Diagnostic Solutions	799		834		1,633		726		803		1,529
Biosciences	260		342		603		228		350		579
Total segment revenues	$	1,060	$	1,176	$	2,236	$	954	$	1,153	$	2,108

Interventional
Surgery (b)	$	505	$	133	$	638	$	488	$	130	$	618
Peripheral Intervention (b)	467		327		794		448		321		769
Urology and Critical Care (b)	409		161		570		388		158		545
Total segment revenues	$	1,381	$	621	$	2,002	$	1,323	$	609	$	1,932

Total Company revenues	$	4,845	$	3,634	$	8,479	$	4,728	$	3,628	$	8,355


(a)	Prior-period amounts reflect the reclassification of U.S. revenues of $3 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.


(b)	Prior-period amounts reflect the total reclassifications of $63 million of U.S. revenues and $28 million of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.

Financial Information for Company's Segments

Segment income for the three and six-month periods was as follows:



	Three Months Ended March 31,						Six Months Ended March 31,
(Millions of dollars)	2020			2019			2020			2019
Income Before Income Taxes
Medical (a) (b)	$	443		$	599		$	1,007		$	1,265
Life Sciences (c)	285			293			646			598
Interventional	213			231			455			441
Total Segment Operating Income	941			1,123			2,109			2,303
Acquisitions and other restructurings	(75		)	(101		)	(161		)	(191		)
Net interest expense	(132		)	(153		)	(266		)	(336		)
Other unallocated items (d)	(534		)	(866		)	(1,087		)	(1,058		)
Total Income Before Income Taxes	$	200		$	3		$	594		$	718

(a)


(b)	The amounts for the three and six-month periods in 2019 included $65 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform.


(c)	The amounts for the three and six-month periods in 2020 include a charge of $39 million recorded to Cost of products sold to write down the carrying value of certain intangible assets in the Biosciences unit.

(d)

Benefit Plans (Tables)

6 Months Ended

Mar. 31, 2020

Retirement Benefits [Abstract]

Net Pension and Postretirement Cost

Net pension cost included the following components for the three and six months ended March 31:



	Three Months Ended March 31,						Six Months Ended March 31,
(Millions of dollars)	2020			2019			2020			2019
Service cost	$	39		$	33		$	79		$	68
Interest cost	21			26			43			54
Expected return on plan assets	(48		)	(45		)	(97		)	(91		)
Amortization of prior service credit	(3		)	(3		)	(7		)	(7		)
Amortization of loss	25			19			50			39
Net pension cost	$	34		$	31		$	68		$	63

Business Restructuring Charges (Tables)

6 Months Ended

Mar. 31, 2020

Restructuring and Related Activities [Abstract]

Summary of Restructuring Accrual Activity

Restructuring liability activity for the six months ended March 31, 2020 was as follows:



(Millions of dollars)	Employee Termination						Other						Total
	Bard			Other Initiatives			Bard (a)			Other Initiatives			Bard			Other Initiatives
Balance at September 30, 2019	$	22		$	31		$	1		$	3		$	23		$	34
Charged to expense	6			(2		)	23			14			29			12
Cash payments	(12		)	(23		)	(5		)	(12		)	(17		)	(35		)
Non-cash settlements	—			—			(16		)	(2		)	(16		)	(2		)
Balance at March 31, 2020	$	16		$	6		3			$	3		$	19		$	9

(a)

Intangible Assets (Tables)

6 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Components of Intangible Assets

Intangible assets consisted of:



	March 31, 2020				September 30, 2019
(Millions of dollars)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Amortized intangible assets
Developed technology	$	13,985	$	3,440	$	13,960	$	2,906
Customer relationships	4,606		1,345		4,608		1,183
Product rights	106		61		110		60
Trademarks	407		110		407		102
Patents and other	493		315		445		305
Amortized intangible assets	$	19,597	$	5,271	$	19,530	$	4,555
Unamortized intangible assets
Acquired in-process research and development (a)	$	46			$	1
Trademarks	2				2
Unamortized intangible assets	$	48			$	3

Reconciliation of Goodwill by Business Segment

The following is a reconciliation of goodwill by business segment:



(Millions of dollars)	Medical			Life Sciences			Interventional			Total
Goodwill as of September 30, 2019	$	9,989		$	772		$	12,615		$	23,376
Acquisitions (a)	10			58			—			68
Currency translation	(2		)	(1		)	(26		)	(29		)
Goodwill as of March 31, 2020	$	9,997		$	828		$	12,589		$	23,415

(a)

Represents goodwill recognized relative to certain acquisitions which were not material individually or in the aggregate.

Derivative Instruments and Hedging Activities (Tables)

6 Months Ended

Mar. 31, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)

Net gains (losses) recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges for the three and six-month periods were as follows:



	Three Months Ended March 31,					Six Months Ended March 31,
(Millions of dollars)	2020		2019			2020		2019
Foreign currency-denominated debt	$	44	$	(18	)	$	10	$	41
Cross-currency swaps	$	193	$	—		$	141	$	—

Financial Instruments and Fair Value Measurements (Tables)

6 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Schedule of Cash and Cash Equivalents



(Millions of dollars)	March 31, 2020		September 30, 2019
Cash and equivalents	$	2,351	$	536
Restricted cash	88		54
Cash and equivalents and restricted cash	$	2,439	$	590

Leases (Tables)

6 Months Ended

Mar. 31, 2020

Leases [Abstract]

Supplemental Balance Sheet Information Related to Leases [Table Text Block]

The right-of-use assets and lease liabilities recognized on the Company’s condensed consolidated balance sheet as of March 31, 2020 were as follows:



(Millions of dollars)	March 31, 2020
Right-of-use assets recorded in Other Assets	$	427
Current lease liabilities recorded in Payables, accrued expenses and other current liabilities	$	103
Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities	$	345

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

The Company’s payments due under its operating leases are as follows:



(Millions of dollars)
Remaining for 2020	$	58
2021	102
2022	83
2023	55
2024	36
Thereafter	164
Total payments due	499
Less: imputed interest	50
Total	$	448

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

The Company’s future minimum rental commitments on non-cancelable leases at September 30, 2019, as disclosed in the Company’s 2019 Annual Report on Form 10-K, were as follows:



(Millions of dollars)
2020	$	122
2021	103
2022	83
2023	57
2024	56
Thereafter	123
Total	$	546

Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended				6 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2020	Mar. 31, 2019
Dividends per Common Share (USD per share)	$ 0.79	$ 0.79	$ 0.77	$ 0.77	$ 1.58	$ 1.54
Beginning balance		$ 21,081			$ 21,081
Net income	$ 183		$ 20		461	$ 619
Ending balance	20,951				20,951
Common Stock Issued at Par Value
Beginning balance	347	347	347	$ 347	347	347
Ending balance	347	347	347	347	347	347
Capital in Excess of Par Value
Beginning balance	16,320	16,270	16,174	16,179	16,270	16,179
Common stock issued for share-based compensation and other plans, net	(91)	(32)	(57)	(97)
Share-based compensation	58	82	60	92
Ending balance	16,288	16,320	16,177	16,174	16,288	16,177
Retained Earnings
Beginning balance	12,938	12,913	13,018	12,596	12,913	12,596
Net income		278	20	599
Common dividends	(215)	(215)	(208)	(207)
Preferred dividends	(38)	(38)	(38)	(38)
Common stock issued for share-based compensation and other plans, net			(1)
Effect of changes in accounting principle				68
Ending balance	12,868	12,938	12,792	13,018	12,868	12,792
Deferred Compensation
Beginning balance	24	23	24	22	23	22
Common stock issued for share-based compensation and other plans, net	(1)	1	(1)	2
Ending balance	23	24	23	24	23	23
Treasury Stock
Beginning balance	$ (6,228)	$ (6,190)	$ (6,235)	$ (6,243)	$ (6,190)	$ (6,243)
Beginning balance (shares)	(75,514)	(76,260)	(77,624)	(78,463)	(76,260)	(78,463)
Common stock issued for share-based compensation and other plans, net	$ 70	$ (38)	$ 42	$ 9
Common stock issued for share-based compensation and other plans, net (in shares)	573	758	618	851
Common stock held in trusts, net	30	(12)	50	(12)
Ending balance	$ (6,158)	$ (6,228)	$ (6,192)	$ (6,235)	$ (6,158)	$ (6,192)
Ending balance (shares)	(74,911)	(75,514)	(76,955)	(77,624)	(74,911)	(76,955)

Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive income (loss), net of tax, beginning balance	$ (2,202)	$ (2,283)	$ (1,927)	$ (1,909)
Other comprehensive income before reclassifications, net of taxes	(237)	63	74	(32)
Amounts reclassified into income, net of taxes	19	19	14	14
Accumulated other comprehensive income (loss), net of tax, ending balance	(2,419)	(2,202)	(1,839)	(1,927)
Foreign Currency Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive income (loss), net of tax, beginning balance	(1,230)	(1,256)	(1,197)	(1,162)
Other comprehensive income before reclassifications, net of taxes	(125)	26	76	(35)
Amounts reclassified into income, net of taxes	0	0	0	0
Accumulated other comprehensive income (loss), net of tax, ending balance	(1,355)	(1,230)	(1,121)	(1,197)
Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive income (loss), net of tax, beginning balance	(988)	(1,005)	(714)	(729)
Other comprehensive income before reclassifications, net of taxes	0	0	0	3
Amounts reclassified into income, net of taxes	17	17	13	13
Accumulated other comprehensive income (loss), net of tax, ending balance	(971)	(988)	(701)	(714)
Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive income (loss), net of tax, beginning balance	16	(23)	(16)	(17)
Other comprehensive income before reclassifications, net of taxes	(111)	37	(2)	(1)
Amounts reclassified into income, net of taxes	2	2	1	1
Accumulated other comprehensive income (loss), net of tax, ending balance	$ (93)	$ 16	$ (17)	$ (16)

Earnings Per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings per Share (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Average common shares outstanding (shares)	272,014	269,882	271,555	269,454
Dilutive share equivalents from share-based plans (shares)	3,023	0	3,618	4,975
Average common and common equivalent shares outstanding - assuming dilution (shares)	275,037	269,882	275,173	274,429
Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	11,685	11,685	11,685	11,685
Share Based Compensation
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	0	4,405	0	0

Earnings per Share Additional Information (Details) - shares shares in Thousands	May 01, 2020	Mar. 31, 2020
Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred Stock, Shares Outstanding		2,475
Subsequent Event
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion	11,703

Contingencies - Additional Information (Detail) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2018 USD ($)	Sep. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)
Loss Contingencies [Line Items]
Loss contingency accrual		$ 2,500		$ 2,300
Qualified settlement funds		53		87
Loss contingency, receivable		150		$ 117
Other Operating Income (Expense)
Loss Contingencies [Line Items]
Product liability accrual, period expense		$ 582	$ 331		$ 331
Hernia Product Claims
Loss Contingencies [Line Items]
Pending claims				16,815
Womens Health Product Claims
Loss Contingencies [Line Items]
Pending claims				580
Claims lacking sufficient information				1,005
PaymentstoSupplier				$ 141
Number of claims in settlement agreement				15,220
Damages awarded	$ 68
Womens Health Product Claims \| Compensatory
Loss Contingencies [Line Items]
Damages awarded	33
Womens Health Product Claims \| Punitive
Loss Contingencies [Line Items]
Damages awarded	$ 35
Filter Product Claims
Loss Contingencies [Line Items]
Pending claims				1,785
Loss Contingency, Claims Settled, Number				7,300

Revenues - Additional Information (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01 $ in Billions	Mar. 31, 2020 USD ($)
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction	3 years
Products and/or Services
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 1.7
Consumables
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 2.7

Segment Data - Additional Information (Detail)	6 Months Ended
Segment Data - Additional Information (Detail)	Mar. 31, 2020 segment
Segment Reporting [Abstract]
Number of principal business segments (segment)	3

Segment Data - Revenues by Geographic Areas (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenues	$ 4,253	$ 4,195	$ 8,479	$ 8,355
Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	2,151	2,180	4,241	4,316
Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	1,113	1,052	2,236	2,108
Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	990	963	2,002	1,932
United States
Segment Reporting Information [Line Items]
Revenues	2,415	2,341	4,845	4,728
United States \| IVFluids
Segment Reporting Information [Line Items]
Revenues		2		3
United States \| InterventionalSpecialties,BrachytherapyandFeedingProducts
Segment Reporting Information [Line Items]
Revenues		31		63
United States \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	1,200	1,211	2,404	2,450
United States \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	522	470	1,060	954
United States \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	693	659	1,381	1,323
International
Segment Reporting Information [Line Items]
Revenues	1,839	1,854	3,634	3,628
International \| InterventionalSpecialties,BrachytherapyandFeedingProducts
Segment Reporting Information [Line Items]
Revenues		13		28
International \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	951	969	1,836	1,865
International \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	591	582	1,176	1,153
International \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	297	303	621	609
Medication Delivery Solutions \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	904	928	1,852	1,884
Medication Delivery Solutions \| United States \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	518	482	1,038	1,000
Medication Delivery Solutions \| International \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	386	446	814	883
Medication Management Solutions \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	568	617	1,143	1,242
Medication Management Solutions \| United States \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	449	499	912	1,007
Medication Management Solutions \| International \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	119	118	231	236
Diabetes Care \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	278	270	547	544
Diabetes Care \| United States \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	142	137	281	282
Diabetes Care \| International \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	137	133	266	261
Pharmaceutical Systems \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	400	366	699	646
Pharmaceutical Systems \| United States \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	91	93	174	161
Pharmaceutical Systems \| International \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	309	273	525	485
Preanalytical Systems \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	400	366	798	758
Preanalytical Systems \| United States \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	208	171	410	371
Preanalytical Systems \| International \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	192	195	388	387
Diagnostic Systems \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	434	389	835	771
Diagnostic Systems \| United States \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	206	180	390	355
Diagnostic Systems \| International \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	228	209	446	416
Integrated Diagnostic Solutions \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	833	755	1,633	1,529
Integrated Diagnostic Solutions \| United States \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	413	350	799	726
Integrated Diagnostic Solutions \| International \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	420	404	834	803
Biosciences \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	280	297	603	579
Biosciences \| United States \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	108	120	260	228
Biosciences \| International \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	172	177	342	350
Surgery \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	312	308	638	618
Surgery \| United States \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	249	242	505	488
Surgery \| International \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	63	66	133	130
Peripheral Intervention \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	399	387	794	769
Peripheral Intervention \| United States \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	242	225	467	448
Peripheral Intervention \| International \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	157	162	327	321
Urology and Critical Care \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	279	268	570	545
Urology and Critical Care \| United States \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	202	193	409	388
Urology and Critical Care \| International \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	$ 76	$ 75	$ 161	$ 158

Segment Data - Financial Information for Company's Segments (Detail) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Income (Loss) Before Income Taxes	$ 200		$ 3	$ 594	$ 718
Acquisitions and other restructurings	(75)		(101)	(161)	(191)
Inventory Recall Expense	199		65	258	65
Gain on sale of business				0	335
Advanced Bioprocessing
Segment Reporting Information [Line Items]
Gain on sale of business			335
Other Operating Income (Expense)
Segment Reporting Information [Line Items]
Product liability accrual, period expense		$ 582	331		331
Life Sciences
Segment Reporting Information [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)	39			39
Operating Segments
Segment Reporting Information [Line Items]
Income (Loss) Before Income Taxes	941		1,123	2,109	2,303
Operating Segments \| Medical
Segment Reporting Information [Line Items]
Income (Loss) Before Income Taxes	443		599	1,007	1,265
Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Income (Loss) Before Income Taxes	285		293	646	598
Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Income (Loss) Before Income Taxes	213		231	455	441
Segment Reconciling Items
Segment Reporting Information [Line Items]
Acquisitions and other restructurings	(75)		(101)	(161)	(191)
Net interest expense	(132)		(153)	(266)	(336)
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Income (Loss) Before Income Taxes	$ (534)		$ (866)	$ (1,087)	$ (1,058)

Benefit Plans - Net Pension and Postretirement Cost (Detail) - Pension Plans - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 39	$ 33	$ 79	$ 68
Interest cost	21	26	43	54
Expected return on plan assets	(48)	(45)	(97)	(91)
Amortization of prior service credit	(3)	(3)	(7)	(7)
Amortization of loss	25	19	50	39
Net pension and postretirement cost	$ 34	$ 31	$ 68	$ 63

Divestiture - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on disposition of business		$ 0	$ 335
Advanced Bioprocessing
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on disposition of business	$ 335

Business Restructuring Charges - Summary of Restructuring Accrual Activity (Detail) $ in Millions	6 Months Ended
	Mar. 31, 2020 USD ($)
CR Bard Inc
Restructuring Reserve [Roll Forward]
Balance at September 30, 2019	$ 23
Charged to expense	29
Cash payments	(17)
Non-cash settlements	(16)
Balance at March 31, 2020	19
CR Bard Inc \| Employee Termination
Restructuring Reserve [Roll Forward]
Balance at September 30, 2019	22
Charged to expense	6
Cash payments	(12)
Non-cash settlements	0
Balance at March 31, 2020	16
CR Bard Inc \| Other Restructuring
Restructuring Reserve [Roll Forward]
Balance at September 30, 2019	1
Charged to expense	23
Cash payments	(5)
Non-cash settlements	(16)
Balance at March 31, 2020	3
Other Initiatives
Restructuring Reserve [Roll Forward]
Balance at September 30, 2019	34
Charged to expense	12
Cash payments	(35)
Non-cash settlements	(2)
Balance at March 31, 2020	9
Other Initiatives \| Employee Termination
Restructuring Reserve [Roll Forward]
Balance at September 30, 2019	31
Charged to expense	(2)
Cash payments	(23)
Non-cash settlements	0
Balance at March 31, 2020	6
Other Initiatives \| Other Restructuring
Restructuring Reserve [Roll Forward]
Balance at September 30, 2019	3
Charged to expense	14
Cash payments	(12)
Non-cash settlements	(2)
Balance at March 31, 2020	$ 3

Intangible Assets - Components of Intangible Assets (Detail) - USD ($) $ in Millions	Mar. 31, 2020	Sep. 30, 2019
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 19,597	$ 19,530
Accumulated Amortization	5,271	4,555
Unamortized intangible assets	48	3
Trademarks
Finite And Indefinite Lived Intangible Assets [Line Items]
Unamortized intangible assets	2	2
Acquired in-process research and development (a)
Finite And Indefinite Lived Intangible Assets [Line Items]
Unamortized intangible assets	46	1
Developed technology
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	13,985	13,960
Accumulated Amortization	3,440	2,906
Customer relationships
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,606	4,608
Accumulated Amortization	1,345	1,183
Product rights
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	106	110
Accumulated Amortization	61	60
Trademarks
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	407	407
Accumulated Amortization	110	102
Patents and other
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	493	445
Accumulated Amortization	$ 315	$ 305

Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible amortization expense	$ 347	$ 376	$ 693	$ 754

Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail) $ in Millions	6 Months Ended
	Mar. 31, 2020 USD ($)
Goodwill [Roll Forward]
Goodwill as of September 30, 2019	$ 23,376
Goodwill, Acquired During Period	68
Currency translation	(29)
Goodwill as of March 31, 2020	23,415
Medical
Goodwill [Roll Forward]
Goodwill as of September 30, 2019	9,989
Goodwill, Acquired During Period	10
Currency translation	(2)
Goodwill as of March 31, 2020	9,997
Life Sciences
Goodwill [Roll Forward]
Goodwill as of September 30, 2019	772
Goodwill, Acquired During Period	58
Currency translation	(1)
Goodwill as of March 31, 2020	828
Interventional
Goodwill [Roll Forward]
Goodwill as of September 30, 2019	12,615
Goodwill, Acquired During Period	0
Currency translation	(26)
Goodwill as of March 31, 2020	$ 12,589

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2020	Mar. 31, 2020	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Reclassification of terminated interest rate swaps to interest expense within the next 12 months	$ (6)	$ (6)
Debt \| Net Investment Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	1,400	1,400	$ 1,400
Foreign Exchange Contract
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	1,200	1,200	2,300
Currency Swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	3,000	3,000	2,300
Fixed to Floating \| Fair Value Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	375	375
Interest Rate Swap \| Cash Flow Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	1,500	1,500	$ 1,500
Unrealized Gain (Loss) on Cash Flow Hedging Instruments	(111)	(74)
Commodity Contract \| Cash Flow Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	$ 0	$ 0

Derivative Instruments and Hedging Activities Disclosure - Gains (Losses) on Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Foreign Currency-Denominated Debt
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	$ 44	$ (18)	$ 10	$ 41
Currency Swap
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	$ 193	$ 0	$ 141	$ 0

Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Cash and equivalents	$ 2,351	$ 536
Restricted cash	88	54
Cash and equivalents and restricted cash	$ 2,439	$ 590	$ 767	$ 1,236

Financial Instruments and Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2020	Mar. 31, 2020	Sep. 30, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, fair value	$ 1,800	$ 1,800	$ 39
Remaining cash equivalents	516	516	497
Fair value of long-term debt	17,200	17,200	19,200
Fair value of debt reclassified from long term to short term	2,400	2,400	$ 1,300
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized	246	246
Life Sciences
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)	$ 39	$ 39
Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase		3 months
Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase		1 year

Debt - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Apr. 01, 2020	Mar. 20, 2020
Term Loan Facility
Debt Instrument [Line Items]
Debt Instrument, Term	364 days
Line of Credit Facility, Current Borrowing Capacity	$ 2,000		$ 1,400
Long-term Line of Credit	1,900
Revolving Credit Facility
Debt Instrument [Line Items]
Line of Credit Facility, Current Borrowing Capacity	2,250
Long-term Line of Credit	$ 695
Revolving Credit Facility \| Subsequent Event
Debt Instrument [Line Items]
Line of Credit Facility, Current Borrowing Capacity		$ 2,630
Line of Credit Facility, Additional Borrowing Capacity		$ 381

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

Leases - Additional Information (Details) $ in Millions	3 Months Ended	6 Months Ended
Leases - Additional Information (Details) $ in Millions	Mar. 31, 2020 USD ($)	Mar. 31, 2020 USD ($)
Lessee, Lease, Description [Line Items]
Operating Lease, Weighted Average Remaining Lease Term	7 years 6 months	7 years 6 months
Operating Lease, Weighted Average Discount Rate, Percent	2.30%	2.30%
Lease, Cost	$ 32	$ 65
Minimum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	25 years	25 years

Leases - Supplemental Balance Sheet Information Related to Leases (Details) $ in Millions	Mar. 31, 2020 USD ($)
Leases [Abstract]
Right-use-assets recorded in Other Assets	$ 427
Current lease liabilities recorded in Payables, accrued expenses and other current liabilities	103
Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities	$ 345

Leases - Lessee, Operating Lease, Liability, Maturity (Details) $ in Millions	Mar. 31, 2020 USD ($)
Leases [Abstract]
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 58
Lessee, Operating Lease, Liability, Payments, Due Year Two	102
Lessee, Operating Lease, Liability, Payments, Due Year Three	83
Lessee, Operating Lease, Liability, Payments, Due Year Four	55
Lessee, Operating Lease, Liability, Payments, Due Year Five	36
Lessee, Operating Lease, Liability, Payments, Due after Year Five	164
Lessee, Operating Lease, Liability, Payments, Due	499
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	50
Operating Lease, Liability	$ 448

Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) $ in Millions	Sep. 30, 2019 USD ($)
Leases [Abstract]
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$ 122
Operating Leases, Future Minimum Payments, Due in Two Years	103
Operating Leases, Future Minimum Payments, Due in Three Years	83
Operating Leases, Future Minimum Payments, Due in Four Years	57
Operating Leases, Future Minimum Payments, Due in Five Years	56
Operating Leases, Future Minimum Payments, Due Thereafter	123
Operating Leases, Future Minimum Payments Due	$ 546